Thermic Sciences International
Other OTCCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Raymond C. Dabney
- Full Time Employees
- 2,955
- Sector
- Technology
- Industry
- Communication Equipment
- Address
- 2910 North Powers Boulevard Colorado Springs CO United States of America 80922
- IPO Date
- Feb 1, 1995
- CIK
- 0000054424
- Website
- omnicanna.com
- Similar Companies
- Business
- Thermic Sciences International Corp (OTC: ENDO) develops and sells hemp-based health and wellness products, including cosmeceuticals such as Hempery miracle oil, Hemp milk body wash, Hemp lotion bars, Hemp rose soap, and Hemtastique lip and body balms; nutraceuticals; and food brands like HempTasty spices and sauces under its Hempery and HempTasty brands, alongside Thermic brand heating products comprising Thermic Heating Paint and Portable Thermic Heating Units. The company also pursues cannabinoid drug development targeting ailments including HIV/AIDS, asthma, cancer, glaucoma, influenza, pain management, and post-traumatic stress disorder, while operating as a conglomerate special purpose acquisition company focused on education, job creation, and diversified ventures such as digital immersion hubs and banking services. Founded in 1969 and headquartered in Colorado Springs, Colorado, Thermic Sciences International distributes its offerings across the United States, Canada, Colombia, Ireland, India, China, Japan, South Korea, and Afghanistan via online platforms and retail stores; it owns subsidiaries including Cannabis Science Inc. and Thermic Coating Systems Ltd., and was formerly known as OmniCanna Health Solutions, Inc. Recent developments include the acquisition of UK-based VIPOnline Ltd. to establish a Thermic Banking System integrating traditional and cryptocurrency services, progress toward completing the acquisition of Cannabis Science Inc. with uplisting efforts via Form 10 Registration Statement filing, and launches of infrared portable heaters alongside prototypes for Seebeck-based solid-state ceramic renewable battery power applications.
Soleno Therapeutics Presents New VYKAT® XR (diazoxide choline) Data at ENDO 2026 Demonstrating Meaningful and Durable Improvements in Hyperphagia and Behavioral Symptoms in Prader-Willi Syndrome Following Randomized Withdrawal Period
Neurocrine Biosciences Presents First Retrospective Case Series of CRENESSITY® (crinecerfont) in Patients with Classic Congenital Adrenal Hyperplasia Due to 11β‑Hydroxylase Deficiency at ENDO 2026
Ethyreal Bio Presents First Preclinical Data on ETHY-001 at ENDO 2026, Demonstrating Complete Blockade of Autoantibody Activation of TSHR and Differentiated Activity in TED
ENDO 2026 Oral Presentation Highlights Comparative Clinical Data for Entera's Breakthrough Single Tablet EB613 (First-in-Class Oral PTH(1-34) Anabolic for Osteoporosis)
Neurocrine Biosciences Presents New Two-Year CRENESSITY® (crinecerfont) Data Demonstrating Improved Growth Measures in Pediatric Patients with Classic Congenital Adrenal Hyperplasia at ENDO 2026
Neurocrine Biosciences Presents New Two-Year CRENESSITY® (crinecerfont) Data Demonstrating Improvements in Cardiometabolic Outcomes in Adults with Classic Congenital Adrenal Hyperplasia at ENDO 2026
Lundbeck presents new Phase II asedebart data in Cushing's disease at ENDO 2026
Crinetics Presents Long Term Data at ENDO 2026 Confirming PALSONIFY™ (paltusotine) Provides Durable, Consistent Acromegaly Control
Mineralys Therapeutics Presents Late-Breaking Data on Lorundrostat and Heart Failure Risk Biomarkers at The Endocrine Society Annual Meeting (ENDO 2026)
Rhythm Pharmaceuticals Presents Positive Interim Six-month Data from Phase 2 Trial of Setmelanotide in Patients with Prader-Willi Syndrome (PWS) at ENDO 2026
Lundbeck to present new patient data on neuroendocrine and neuroimmunology programs at ENDO 2026
Lundbeck to present new patient data on neuroendocrine and neuroimmunology programs at ENDO 2026
Ascendis to Showcase Advances in Treatment of Rare Endocrine Diseases at ENDO 2026
Amylyx Pharmaceuticals Announces Poster Presentations at ENDO 2026
Mineralys Therapeutics to Present Late-Breaking Data on Lorundrostat at The Endocrine Society Annual Meeting (ENDO 2026)
Regeneron to Highlight Progress Across Its Metabolic Disease, Ophthalmology and Rare Disease Pipelines at ADA and ENDO
Neurocrine Biosciences to Present New Two‑Year CRENESSITY® (crinecerfont) Data on Key Clinical and Patient‑Reported Outcome Measures at ENDO 2026
Crinetics' Paradigm-Shifting Portfolio and Pipeline on Display at ENDO 2026 with Six Presentations
Rhythm Pharmaceuticals Announces Seven Abstracts Accepted for Presentation at ENDO 2026
Neurocrine Biosciences Presents New Analysis of CAHtalog® Registry Showing Most Patients with Classic Congenital Adrenal Hyperplasia Experienced High Glucocorticoid Exposure, Suboptimal Disease Control or Both at ENDO 2025